Lisata Therapeutics Inc (LTS:0HS8)

$ 3.255 0 (0%) Market Cap: 28.95 Mil Enterprise Value: -14.23 Mil PE Ratio: 0 PB Ratio: 0.67 GF Score: 37/100

Q4 2023 Lisata Therapeutics Inc Earnings Call Transcript
Feb 29, 2024

$3.21 (+4.61%)

Earnings
Q3 2023 Lisata Therapeutics Inc Earnings Call Transcript
Nov 02, 2023

$2.15 (+5.88%)

Earnings
Q2 2023 Lisata Therapeutics Inc Earnings Call Transcript
Aug 15, 2023

$2.71

Earnings
Lisata Therapeutics Inc Fireside Chat Hosted by H.C. Wainwright & Co LLC (Virtual) Transcript
Jun 21, 2023
Q1 2023 Lisata Therapeutics Inc Earnings Call Transcript
May 09, 2023

$3.18

Earnings
Q4 2022 Lisata Therapeutics Inc Earnings Call Transcript
Mar 30, 2023

$3.33

Earnings
Lisata Therapeutics Inc at OTC Markets Life Science Investor Forum (Virtual) Transcript
Mar 09, 2023
Q3 2022 Lisata Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

$4.06

Earnings
Q2 2022 Caladrius Biosciences Inc Earnings Call Transcript
Aug 04, 2022

$7.46 (+0.24%)

Earnings
Caladrius Biosciences Inc Provides Update on Phase 2b FREEDOM Trial Conference Call and Webcast Transcript
May 24, 2022
Q1 2022 Caladrius Biosciences Inc Earnings Call Transcript
May 05, 2022

$7.82

Earnings
Caladrius Biosciences Inc & Cend Therapeutics Definitive Merger Agreement Call Transcript
Apr 27, 2022
Q4 2021 Caladrius Biosciences Inc Earnings Call Transcript
Mar 22, 2022

$10.97 (-1.16%)

Earnings
Q3 2021 Caladrius Biosciences Inc Earnings Call Transcript
Nov 04, 2021

$17.55 (+0.80%)

Earnings
Q2 2021 Caladrius Biosciences Inc Earnings Call Transcript
Aug 05, 2021

$19.79 (+2.68%)

Earnings
Caladrius Biosciences Inc at LD Micro Virtual Zooming Conference Transcript
Jul 29, 2021
Q1 2021 Caladrius Biosciences Inc Earnings Call Transcript
May 06, 2021

$22.65 (-3.08%)

Earnings
Q4 2020 Caladrius Biosciences Inc Earnings Call Transcript
Feb 25, 2021

$29.85 (-2.21%)

Earnings
Q3 2020 Caladrius Biosciences Inc Earnings Call Transcript
Nov 05, 2020

$35.1

Earnings
Q2 2020 Caladrius Biosciences Inc Earnings Call Transcript
Aug 13, 2020

$34.2

Earnings
Caladrius Biosciences Inc Annual Shareholders Meeting Transcript
Jun 18, 2020
Q1 2020 Caladrius Biosciences Inc Earnings Call Transcript
May 07, 2020

$28.2

Earnings
Q4 2019 Caladrius Biosciences Inc Earnings Call Transcript
Mar 05, 2020

$44.25

Earnings
Q3 2019 Caladrius Biosciences Inc Earnings Call Transcript
Nov 06, 2019

$44.25

Earnings
Q2 2019 Caladrius Biosciences Inc Earnings Call Transcript
Aug 08, 2019

$44.25

Earnings
Q1 2019 Caladrius Biosciences Inc Earnings Call Transcript
May 09, 2019

$54

Earnings

Q4 2022 Lisata Therapeutics Inc Earnings Call Transcript

Mar 30, 2023 / 08:30PM GMT

Release Date Price: $3.33

Transcript 10-K8-K

Operator

Welcome to the Lisata Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Business Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, Thursday, March 30, 2023. I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communication at Lisata. Please go ahead, sir.

John D. Menditto

Lisata Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you, operator, and good afternoon, everyone. Welcome to Lisata's fourth quarter and full year 2022 conference call to discuss our financial results and provide a business update.

Joining me today from our management team are Dr. David Mazzo, Chief Executive Officer; Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer; and James Nisco, Vice President of Finance and Treasury.

Shortly before this call, we issued a press release announcing our fourth quarter and full-year 2022 financial results, which is available under the Investors and News

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.